Aptose Biosciences Enters US$11.9M Amended Loan Facility with Hanmi Pharmaceutical

On September 22, 2025, Aptose Biosciences Inc. (“Aptose”) entered into a US$11.9 million amended loan facility agreement (the “Facility Agreement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”). This Facility Agreement has been amended and restated from the prior June 2025 Facility Agreement between Hanmi and Aptose.

The Facility Agreement is uncommitted and administered through multiple advances until December 31, 2025, and will be used to fund Aptose’s business and clinical operations expenses related to the advancement of a tuspetinib (TUS)-based triple drug frontline therapy for newly diagnosed acute myeloid leukemia.

Aptose, headquartered in Toronto, Ontario, is a Canadian clinical-stage biotechnology company focused on developing oncology therapies, with an initial focus on hematology.

Hanmi Pharmaceutical, headquartered in Seoul, South Korea, is a global biopharmaceutical company specializing in oncology, diabetes, obesity, and metabolic diseases.

McCarthy Tétrault LLP advised Aptose with a team led by Charles-Antoine Soulière, Farhiyah Shariff, and Audrey Bouffard-Nesbitt that included Kayla Ellison, Yassine Khadir (Business Law), Rhea Evans (Financial Services), Jamey Gage (Bankruptcy & Restructuring), and Michel Ranger (Tax).